1 Global Infectious Diseases Diagnostic Market Size (Revenue) and CAGR (2024-2033)
Global Infectious Diseases Diagnostic market generated revenue of USD 27654 Million in 2024 with a CAGR of 4.07% during 2024 to 2033.
The current situation of the Infectious Diseases Diagnostic market is characterized by growth and development. This growth is driven by various factors including the increasing prevalence of infectious diseases, the need for early diagnosis, advancements in medical infrastructure, and the development of diagnostic testing technology. Governments and commercial organizations have increased their investment in the market, leading to the expansion of medical laboratories used for the diagnosis and testing of infectious diseases. The market is also influenced by the emergence of new infectious diseases and the changing spectrum of existing ones, which creates new demands and opportunities for research and development in diagnostic methods. However, the market also faces challenges such as stricter industry regulations, policy risks, and intensified market competition. Despite these challenges, the market is expected to continue growing, with a CAGR of 4.07% from 2024 to 2033.
Figure Global Infectious Diseases Diagnostic Market Size (M USD) Outlook (2024-2033)
2 Infectious Diseases Diagnostic Trends Analysis
Market development trend in the region: the demand of Infectious Diseases Diagnostic in the downstream is mainly related to the economic development and medical service level of countries and regions. On the whole, due to the early development of Infectious Diseases Diagnostic industry in developed countries such as Europe and America, the diagnosis market is mature and the downstream demand is strong, while Infectious Diseases Diagnostic in emerging developing countries develops late and the terminal demand gap is large. However, in recent years, with the rapid development of economy and various high-tech and the gradual improvement of medical insurance policies, the emerging developing countries have promoted the rapid expansion of the demand for Infectious Diseases Diagnostic, and their market space will be broad in the future.
Industry development trend: The outbreak of the novel coronavirus epidemic highlights the importance of rapid, efficient and accurate detection means to curb the spread of infectious diseases. Since then, countries are bound to pay more attention to the detection of infectious diseases. Because of the high technical and performance requirements, and the price is only a secondary consideration, large hospitals still mainly purchase traditional major brands, while other brands still have a certain gap in detection accuracy and stability.
Technology development trend: POCT products have many advantages such as high speed, small space and convenient use, and their prices are generally low, which can meet the clinical detection needs of various medical institutions, especially those lacking laboratory conditions for infectious diseases. Therefore, POCT products have obvious advantages in detecting large-scale outbreaks of infectious diseases. Considering that one of the key requirements for the prevention and treatment of infectious diseases is to quickly detect and cut off the transmission route, POCT products are more suitable for regional institutions and general hospitals to quickly identify pathogens without professional laboratories because of their precision, closure and automation. Therefore, POCT products have huge market demand, and thus become the key research and development direction.
3 Global Infectious Diseases Diagnostic Market by Type in 2024
The global Infectious Diseases Diagnostic market encompasses various product types, each with distinct characteristics and market dynamics. In 2024, the market was segmented into Urine, Blood, and Others, with Blood diagnostics holding the largest market share.
Urine Diagnostics Urine diagnostics involve the analysis of urine samples to detect the presence of infectious agents. This method is non-invasive and relatively simple, making it a common choice for initial screenings. In 2024, the urine diagnostics market was valued at 4,065 million USD, accounting for approximately 14.7% of the total market share. Despite its widespread use, the growth rate of this segment was relatively modest, reflecting its maturity in the market and the limitations in detecting certain types of infections.
Blood Diagnostics Blood diagnostics is the most prevalent and critical segment in the Infectious Diseases Diagnostic market. It involves the examination of blood samples to identify a wide range of infectious diseases, from viral infections like HIV and hepatitis to bacterial infections. In 2024, the blood diagnostics market was significantly larger, valued at 18,452 million USD, which constituted about 66.7% of the total market share. This segment’s dominance is attributed to its ability to provide comprehensive and accurate diagnostic information, essential for the management of severe and chronic infectious diseases. The growth rate of blood diagnostics was steady, driven by the continuous need for accurate and reliable testing methods in clinical settings.
In summary, while blood diagnostics held the largest market share in 2024 due to its critical role in diagnosing a broad spectrum of infectious diseases, the Urine Diagnostics category showed the most promise in terms of growth, indicating a trend towards more specialized and diverse diagnostic approaches in the field of infectious diseases.
Table Global Infectious Diseases Diagnostic Market Size and Share by Type in 2024
Type | Market Size (M USD) | Market Share |
|---|---|---|
Urine | 4,065 | 14.7% |
Blood | 18,452 | 66.7% |
Others | 5,137 | 18.6% |
4 Global Infectious Diseases Diagnostic Market by Application in 2024
The Infectious Diseases Diagnostic market serves multiple applications, each with its own significance and market dynamics. In 2024, the market was primarily applied in Hospitals and Trauma Centers, Diagnostic Laboratories, Rehabilitation Centers, and Other settings. Among these, Diagnostic Laboratories held the largest market share, while the Hospitals and Trauma Centers segment showed the fastest growth rate.
Hospitals and Trauma Centers Hospitals and Trauma Centers are frontline settings where infectious disease diagnostics are crucial for immediate patient care and treatment. In 2024, this application segment was valued at 12,449 million USD, accounting for approximately 45.0% of the total market share. The growth rate of this segment was notable, reflecting the increasing demand for rapid and accurate diagnostic services in emergency and critical care settings. The need for on-site diagnostic capabilities to manage infectious disease outbreaks and provide timely interventions drove the growth in this segment.
Diagnostic Laboratories Diagnostic Laboratories play a central role in the analysis and interpretation of diagnostic tests. They offer a wide range of services, from routine screenings to specialized tests. In 2024, the market size for diagnostic laboratories was the largest, at 6,829 million USD, representing about 24.7% of the total market share. The steady growth of this segment is attributed to the continuous demand for reliable and high-quality diagnostic services, as well as the expansion of laboratory networks and the adoption of advanced diagnostic technologies.
Rehabilitation Centers Rehabilitation Centers focus on the recovery and rehabilitation of patients who have suffered from infectious diseases. In 2024, the market size for this application was 3,398 million USD, or about 12.3% of the total market share. The growth rate in this segment was moderate, indicating a stable demand for post-acute care and rehabilitation services. As the focus on patient recovery and long-term management of infectious diseases increases, the role of rehabilitation centers in the diagnostic process is expected to grow.
In conclusion, while Diagnostic Laboratories maintained the largest market share in 2024 due to their central role in providing diagnostic services, the Hospitals and Trauma Centers segment exhibited the fastest growth rate, highlighting the critical need for immediate and accurate diagnostics in acute care settings. The market’s diversity in applications reflects the multifaceted nature of infectious disease management, with each segment contributing uniquely to the overall diagnostic landscape.
Table Global Infectious Diseases Diagnostic Market Size and Share by Application in 2024
Application | Market Size (M USD) | Market Share |
|---|---|---|
Hospitals and Trauma Centers | 12,449 | 45.0% |
Diagnostic Laboratories | 6,829 | 24.7% |
Rehabilitation Centers | 3,398 | 12.3% |
Others | 4,978 | 18.0% |
5 Global Infectious Diseases Diagnostic Market by Region in 2024
In 2024, the global Infectious Diseases Diagnostic market was a dynamic landscape with significant regional variations. North America, Europe, Asia-Pacific, South America, and the Middle East & Africa each contributed uniquely to the overall market revenue, reflecting their respective healthcare infrastructures, economic capacities, and disease prevalence patterns.
North America, comprising the United States, Canada, and Mexico, was a prominent player in the market. The region’s robust healthcare system, high investment in medical research, and advanced diagnostic technologies positioned it as a leader in the field. In 2024, North America’s market revenue reached 8953 million USD, accounting for a substantial share of the global market. The United States, in particular, was a driving force, with its extensive network of diagnostic laboratories and hospitals equipped with state-of-the-art facilities. Canada and Mexico also contributed significantly, with growing demands for infectious disease diagnostics due to increasing health awareness and improving healthcare access.
Europe, known for its sophisticated healthcare services and strong emphasis on medical innovation, was the largest regional market in 2024. With a revenue of 10,311 million USD, Europe held a significant share of the global market. Countries like Germany, the UK, France, and Italy were at the forefront, leveraging their advanced medical technologies and research capabilities to develop and deploy cutting-edge diagnostic solutions. The region’s focus on early detection and prevention of infectious diseases, coupled with a well-established healthcare infrastructure, facilitated the growth and expansion of the diagnostic market.
The Asia-Pacific region, encompassing countries like China, Japan, South Korea, India, and Australia, was a rapidly emerging market in the field of infectious disease diagnostics. In 2024, the region’s market revenue was 6529 million USD. The growth was primarily driven by China and India, which had large populations and growing healthcare demands. These countries invested heavily in upgrading their healthcare facilities and adopting advanced diagnostic technologies to address the challenges posed by infectious diseases. The region’s market was characterized by a mix of high-tech solutions and traditional diagnostic methods, reflecting the diverse economic and healthcare development stages of the countries involved.
South America, with Brazil and Argentina as key players, had a market revenue of 968 million USD in 2024. The region’s market was influenced by its unique disease profiles and the need to address public health challenges. The growth was moderate but steady, with increasing focus on improving healthcare access and diagnostic capabilities. The region’s efforts to combat infectious diseases through better diagnostics were evident in the growing number of diagnostic centers and the adoption of new technologies.
The Middle East & Africa region, although smaller in market size with a revenue of 892 million USD in 2024, was a region of strategic importance. Countries like Saudi Arabia, the UAE, and Turkey were investing in modernizing their healthcare sectors, which included the expansion of infectious disease diagnostic capabilities. The region’s market growth was driven by the need to improve public health outcomes and the increasing awareness of the importance of early diagnosis in disease management.
Among these regions, Europe was the largest regional market by revenue in 2024, with a significant lead over other regions. Its strong healthcare infrastructure, advanced medical technologies, and focus on medical innovation contributed to its dominant position. However, the fastest-growing region was the Asia-Pacific, driven by the rapid economic development of countries like China and India, which were investing heavily in healthcare and diagnostics. The region’s growth was also fueled by the increasing prevalence of infectious diseases and the need for better diagnostic tools to manage public health challenges.
Table Global Infectious Diseases Diagnostic Market Size, Region Wise in 2024
Region | Market Size (M USD) | Market Share |
|---|---|---|
North America | 8953 | 32.38% |
Europe | 10311 | 37.29% |
Asia-Pacific | 6529 | 23.61% |
South America | 968 | 3.50% |
Middle East & Africa | 892 | 3.22% |
Figure Global Infectious Diseases Diagnostic Market Revenue Share, Region Wise in 2024
6 Global Infectious Diseases Diagnostic Market Top 3 Players
Introduction and Business Overview Abbott Laboratories, established in 1888 and headquartered in the United States, is a global healthcare company with a diverse portfolio of products and services. The company is renowned for its innovative approach to healthcare, focusing on diagnostics, nutritional products, and pharmaceuticals. Abbott’s commitment to research and development has led to the creation of advanced diagnostic solutions that address a wide range of medical needs.
Products Offered Abbott’s Infectious Diseases Diagnostic products include a variety of tests and analyzers designed to detect and monitor infectious diseases. Their Alinity m system is a fully integrated and automated molecular diagnostics analyzer that offers flexibility and efficiency in laboratory settings. The company also provides a range of assays for the detection of specific pathogens, such as SARS-CoV-2, influenza, and hepatitis, among others. Abbott’s products are designed to provide rapid and accurate results, aiding in the early diagnosis and treatment of infectious diseases.
Revenue in 2021 In 2021, Abbott Laboratories reported a revenue of 7,405 million USD in the Infectious Diseases Diagnostic market. This significant revenue reflects Abbott’s strong market position and its ability to deliver high-quality diagnostic solutions to healthcare providers worldwide.
Introduction and Business Overview Roche Diagnostics, a division of Roche Holding AG, is a global leader in the development and manufacturing of medical and diagnostic products. Founded in 1896 and headquartered in Switzerland, Roche has a long history of innovation in the field of diagnostics. The company’s products are used in various medical settings, including hospitals, diagnostic laboratories, and research institutions, to provide accurate and reliable diagnostic information.
Products Offered Roche’s Infectious Diseases Diagnostic portfolio includes a wide range of tests and systems designed to detect and monitor infectious diseases. Their cobas® 6800/8800 Systems are renowned for their high-throughput capabilities and accurate detection of pathogens such as SARS-CoV-2, influenza, and hepatitis. Roche also offers immunoassays and rapid antibody tests, which are crucial in the diagnosis and management of infectious diseases. The company’s focus on innovation has led to the development of advanced diagnostic solutions that meet the evolving needs of the healthcare industry.
Revenue in 2021 In 2021, Roche Diagnostics reported a revenue of 5,032 million USD in the Infectious Diseases Diagnostic market. This revenue highlights Roche’s continued leadership in the field of diagnostics and its ability to provide comprehensive solutions to healthcare providers across the globe.
Introduction and Business Overview bioMérieux SA, established in 1963 and headquartered in France, is a leading company in the field of in vitro diagnostics. The company specializes in the diagnosis of infectious diseases and pathologies, offering a wide range of products and solutions for medical and industrial applications. bioMérieux’s commitment to innovation and quality has made it a trusted partner for healthcare providers and researchers worldwide.
Products Offered bioMérieux’s Infectious Diseases Diagnostic products include a variety of tests and analyzers designed to detect and identify infectious agents. Their BioFire FilmArray technology is a fully automated system that provides rapid and accurate results for a wide range of respiratory and gastrointestinal pathogens. The company also offers molecular diagnostic tests, such as the SARS-CoV-2 R-GENE® test, which is designed to detect the virus that causes COVID-19. bioMérieux’s products are designed to meet the diverse needs of healthcare providers, from routine screenings to specialized diagnostic tests.
Revenue in 2021 In 2021, bioMérieux SA reported a revenue of 2,801 million USD in the Infectious Diseases Diagnostic market. This revenue underscores bioMérieux’s strong market presence and its ability to deliver innovative diagnostic solutions that address the challenges of infectious diseases.
Table Global Infectious Diseases Diagnostic Revenue Share of Top3 Players in 2021
Company | 2021 |
Abbott Laboratories | 18.56% |
Roche Diagnostics | 12.62% |
bioMerieux SA | 7.02% |